Doceree offers glimpse into trends of ‘programmatic marketing’news2022-01-20T12:39:53+00:00January 20th, 2022|Fierce Pharma|
No deal for GSK consumer health: Unilever stops raising $68B bid amid investor pushbacknews2022-01-20T12:15:24+00:00January 20th, 2022|Fierce Pharma|
COVID vaccines help Pfizer, Moderna reign supreme reputation-wise, but they’re a double-edged sword for J&J and AZnews2022-01-20T11:49:35+00:00January 20th, 2022|Fierce Pharma|
Gilead says counterfeiters sold $250M worth of fake HIV drugs, sues distributorsnews2022-01-20T05:19:19+00:00January 20th, 2022|Fierce Pharma|
Fierce JPM Week: Novo Nordisk plans more patient outreach, doctor education as Wegovy launch works through supply woesnews2022-01-19T17:51:53+00:00January 19th, 2022|Fierce Pharma|
Fierce JPM Week: Game recognizes game—Lilly, Novartis execs commend Pfizer on Paxlovid, but where does that leave them in the COVID market?news2022-01-19T16:47:56+00:00January 19th, 2022|Fierce Pharma|
Harvard offshoot 64x Bio nets $55M in series A funding to expand cell production technews2022-01-19T16:03:51+00:00January 19th, 2022|Fierce Pharma|
UCB buys rare disease drugmaker Zogenix for up to $1.9B, bolstering its epilepsy positionnews2022-01-19T15:27:49+00:00January 19th, 2022|Fierce Pharma|
Teva ponies up $420M to settle with investors who said company hid price-fixing schemenews2022-01-19T14:53:06+00:00January 19th, 2022|Fierce Pharma|
Did BMS set up a subsidiary to avoid paying $1.4B in U.S. taxes? The Senate finance chairman is on the casenews2022-01-19T14:41:59+00:00January 19th, 2022|Fierce Pharma|
